Saturday, 27 May 2017
Latest news
Main » (BSX) Coverage Initiated by Analysts at Goldman Sachs Group Inc

(BSX) Coverage Initiated by Analysts at Goldman Sachs Group Inc

19 May 2017

Looking at stock performance for the past six months, shares are 23.65%.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Wedge Capital Mgmt L LP Nc holds 0.52% of its portfolio in Boston Scientific Corporation (NYSE:BSX) for 2.48 million shares. Boston Private Wealth LLC now owns 22,890 shares of the medical equipment provider's stock worth $545,000 after buying an additional 85 shares in the last quarter. First Personal Financial Services increased its stake in Boston Scientific by 0.9% in the first quarter. Wade G W & Inc. increased its stake in Boston Scientific by 0.9% in the third quarter. UBS initiated the shares of BSX in report on Tuesday, September 22 with "Buy" rating. They issued a "neutral" rating and a $28.00 target price on the stock. Finally, JNBA Financial Advisors boosted its position in Boston Scientific by 467.9% in the fourth quarter. Hanseatic Management Services Inc. now owns 153,262 shares of the medical equipment provider's stock valued at $3,648,000 after buying an additional 11,147 shares during the last quarter. Guardian Life Insurance Co. of America increased its stake in Boston Scientific by 0.9% in the first quarter.

Boston Scientific Corporation (BSX) belongs to the "Healthcare" sector with an industry focus on "Medical Appliances & Equipment", with Mr. Michael F. Mahoney as Chief Exec. Officer, Pres and Director. About shares traded. Nuveen Select Tax-Free Incom Portfolio 3 (NYSE:NXR) has risen 6.00% since April 19, 2017 and is uptrending.

Since the beginning of the calendar year, the stock is 20.85%. The stock has a market cap of $35.52 billion, a P/E ratio of 83.14 and a beta of 1.06. Boston Scientific has a 12-month low of $19.67 and a 12-month high of $26.76.

House oversight panel calls for May 24 hearing with Comey
Comey also said it made him feel "mildly nauseous" to think his actions in October might have influenced the election outcome. Striking a defiant stance, he added: "You can't let the critics and the naysayers get in the way of your dreams".

In terms of Buy, Sell or Hold recommendations, Boston Scientific Corp (NYSE:BSX) has analysts' mean recommendation of 1.8. The medical equipment provider reported $0.29 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.30 by $0.01.

Boston Scientific Corp (NYSE:BSX)'s trailing twelve month revenues are $8.58 Billion, whereas its price to sales ratio for the same period is 4.16. The firm's quarterly revenue was up 10.0% on a year-over-year basis. During the same period in the previous year, the business earned $0.28 earnings per share.

Shares of the company have shown an EPS growth of -15.50% in the last 5 years.

04/27/2017 - Boston Scientific Corporation had its " rating reiterated by analysts at Needham & Company.

Wenger pins hopes on last-day Arsenal coup
We created opportunities and the players worked really hard. "We were frustrated at half-time not to be leading", said Wenger. We do our job, we have shown that again.

COPYRIGHT VIOLATION WARNING: "Boston Scientific Co".

TRADEMARK VIOLATION NOTICE: This piece of content was published by Markets Daily and is the property of of Markets Daily. The original version of this news story can be read at https://sportsperspectives.com/2017/05/18/boston-scientific-co-bsx-coverage-initiated-at-goldman-sachs-group-inc.html. A rating of 4 or 5 would represent a Sell recommendation.

To stay one step ahead we extended our research by comparing different price targets. By reviewing stock prices from the stock market history of the company and examining its analysts ratings can give an investment picture with updated information of stock which helps investors to make investing decision. Finally, Stifel Nicolaus boosted their price objective on Boston Scientific from $28.00 to $30.00 and gave the stock a "buy" rating in a report on Friday, April 28th.

Ratings analysis reveals 76% of Boston Scientific Corporation's analysts are positive. $248,725 worth of Boston Scientific Corporation (NYSE:BSX) shares were sold by Pratt Timothy A. The insider Sorenson John Bradley sold $72,747. In that case, its shares would mark a 1.57% decline from the most recent price. Following the sale, the senior vice president now directly owns 34,267 shares in the company, valued at approximately $851,192.28. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. The shares were sold at an average price of $24.55, for a total transaction of $1,940,554.75. The disclosure for this sale can be found here. Typically, they estimate what the company's earnings and cash flow will be for the next couple of years, and then apply a ratio - such as a price-to-earnings ratio - to those estimates to determine what the future stock price should theoretically be.

The late Tim Pigott-Smith lauded for performance in King Charles III
When you're trying to emulate Shakespeare, you need to have the pretty verses to pull it off, otherwise it all seems a bit terse. Starring the late Tim Pigott-Smith in his final TV role, it follows Prince Charles shortly after he has become the new king.

About Boston Scientific Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Firm offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.